JP2022523548A5 - - Google Patents
Info
- Publication number
- JP2022523548A5 JP2022523548A5 JP2021552571A JP2021552571A JP2022523548A5 JP 2022523548 A5 JP2022523548 A5 JP 2022523548A5 JP 2021552571 A JP2021552571 A JP 2021552571A JP 2021552571 A JP2021552571 A JP 2021552571A JP 2022523548 A5 JP2022523548 A5 JP 2022523548A5
- Authority
- JP
- Japan
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024176400A JP7852008B2 (ja) | 2019-03-05 | 2024-10-08 | 眼の疾患又は障害を治療するための医薬組成物 |
| JP2024176401A JP7838047B2 (ja) | 2019-03-05 | 2024-10-08 | 眼の疾患又は障害を治療するための医薬組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962814198P | 2019-03-05 | 2019-03-05 | |
| US62/814,198 | 2019-03-05 | ||
| PCT/US2020/021136 WO2020181060A1 (en) | 2019-03-05 | 2020-03-05 | Pharmaceutical compositions for treating ocular diseases or disorders |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024176401A Division JP7838047B2 (ja) | 2019-03-05 | 2024-10-08 | 眼の疾患又は障害を治療するための医薬組成物 |
| JP2024176400A Division JP7852008B2 (ja) | 2019-03-05 | 2024-10-08 | 眼の疾患又は障害を治療するための医薬組成物 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022523548A JP2022523548A (ja) | 2022-04-25 |
| JP2022523548A5 true JP2022523548A5 (https=) | 2023-03-08 |
| JPWO2020181060A5 JPWO2020181060A5 (https=) | 2023-03-08 |
| JP7570342B2 JP7570342B2 (ja) | 2024-10-21 |
Family
ID=72337143
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021552571A Active JP7570342B2 (ja) | 2019-03-05 | 2020-03-05 | 眼の疾患又は障害を治療するための医薬組成物 |
| JP2024176401A Active JP7838047B2 (ja) | 2019-03-05 | 2024-10-08 | 眼の疾患又は障害を治療するための医薬組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024176401A Active JP7838047B2 (ja) | 2019-03-05 | 2024-10-08 | 眼の疾患又は障害を治療するための医薬組成物 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US12478577B2 (https=) |
| EP (1) | EP3934646A4 (https=) |
| JP (2) | JP7570342B2 (https=) |
| KR (1) | KR20210135560A (https=) |
| CN (3) | CN118304422A (https=) |
| AU (1) | AU2020232314C1 (https=) |
| BR (1) | BR112021017436A2 (https=) |
| CA (1) | CA3132635A1 (https=) |
| MX (2) | MX2021010599A (https=) |
| WO (1) | WO2020181060A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2021010599A (es) | 2019-03-05 | 2021-12-10 | Aerie Pharmaceuticals Inc | Composiciones farmaceuticas para el tratamiento de enfermedades o trastornos oculares. |
| CA3166738A1 (en) | 2020-02-06 | 2021-08-12 | Charles D. Blizzard | Travoprost compositions and methods for treating ocular diseases |
| EP3884929B1 (en) | 2020-03-25 | 2023-06-14 | Ocular Therapeutix, Inc. | Ocular implant containing a tyrosine kinase inhibitor |
| WO2021207486A1 (en) * | 2020-04-08 | 2021-10-14 | Aerie Pharmaceuticals, Inc. | Treatments |
| CA3218251A1 (en) | 2021-04-30 | 2022-11-03 | Perfuse Therapeutics, Inc. | Pharmaceutical compositions and intravitreal drug delivery systems for the treatment of ocular diseases |
| WO2022235906A1 (en) | 2021-05-05 | 2022-11-10 | Aerie Pharmaceuticals, Inc. | Pharmaceutical preparation |
| CN120897764A (zh) | 2023-04-11 | 2025-11-04 | 视尔普斯眼科公司 | 包含阿西替尼多晶型物iv的眼部植入物 |
| WO2025146683A1 (en) | 2024-01-03 | 2025-07-10 | Lyotropic Delivery Systems Ltd. | Topical formulations for delivery of an active compound to the back of the eye |
| WO2025169089A1 (en) | 2024-02-05 | 2025-08-14 | Sun Pharmaceutical Industries Limited | Ophthalmic compositions of tyrosine kinase inhibitors and their uses |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2649672C (en) * | 2006-05-02 | 2015-07-07 | Medivas, Llc | Delivery of ophthalmologic agents to the exterior or interior of the eye |
| JP2011518812A (ja) * | 2008-04-25 | 2011-06-30 | ディーエスエム アイピー アセッツ ビー．ブイ． | チオエステル結合を有するポリマーを含む粒子 |
| US9095506B2 (en) | 2008-11-17 | 2015-08-04 | Allergan, Inc. | Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof |
| EP2587304B1 (en) * | 2010-06-22 | 2019-12-18 | Toyobo Co., Ltd. | Liquid crystal display device, polarizer and protective film |
| BR112013018739A2 (pt) * | 2010-12-29 | 2019-09-24 | Jade Therapeutics Inc | sistema de distribuição de medicamento ocular |
| JP6135870B2 (ja) * | 2011-05-02 | 2017-05-31 | ディーエスエム アイピー アセッツ ビー．ブイ． | 生分解性ポリマーを含む繊維 |
| WO2012150255A1 (en) * | 2011-05-02 | 2012-11-08 | Dsm Ip Assets B.V. | Bis-(alpha-amino-diol-diester) containing polyesteramide for ophtamology |
| US20150037422A1 (en) * | 2012-02-22 | 2015-02-05 | Trustees Of Tufts College | Compositions and methods for ocular delivery of a therapeutic agent |
| CA2881729C (en) | 2012-10-02 | 2021-05-04 | Dsm Ip Assets B.V. | Drug delivery composition comprising proteins and biodegradable polyesteramides |
| EP3702394B1 (en) * | 2012-10-24 | 2023-11-22 | DSM IP Assets B.V. | Fibers comprising polyesteramide copolymers for drug delivery |
| CN109602691A (zh) * | 2013-02-15 | 2019-04-12 | 阿勒根公司 | 持续药物递送植入物 |
| ES2834964T3 (es) * | 2013-04-01 | 2021-06-21 | Allergan Inc | Sistema de administración de fármacos mediante microesferas para liberación intraocular sostenida |
| WO2015126477A1 (en) | 2013-11-08 | 2015-08-27 | Tyrx, Inc. | Polymeric drug delivery system for treating surgical complications |
| MX2016007345A (es) * | 2013-12-06 | 2016-12-09 | Envisia Therapeutics Inc | Implante intracameral para el tratamiento de una condicion ocular. |
| WO2015095772A2 (en) * | 2013-12-20 | 2015-06-25 | Emory University | Formulations and methods for targeted ocular delivery of therapeutic agents |
| CN109481447A (zh) * | 2014-09-06 | 2019-03-19 | 整体生物系统有限责任公司 | 用于在眼中实现持续药物释放的方法和生物相容性组合物 |
| EP3233067B1 (en) * | 2014-12-18 | 2019-11-06 | DSM IP Assets B.V. | Drug delivery system for delivery of acid sensitive drugs |
| EP3324944A4 (en) | 2015-07-23 | 2019-04-03 | Aerie Pharmaceuticals, Inc. | INTRAVITREAL AGGREGATION SYSTEMS FOR THE TREATMENT OF EYE DISEASE |
| WO2017120600A1 (en) | 2016-01-08 | 2017-07-13 | Clearside Biomedical, Inc. | Compositions and methods of treating wet age-related macular degeneration |
| US20180117148A1 (en) * | 2016-10-28 | 2018-05-03 | Andrew J. Holman | Compounds, pharmaceutical compositions and methods of treatments of immune related diseases and disorders |
| WO2018161035A1 (en) * | 2017-03-03 | 2018-09-07 | Macregen, Inc. | Treatment of age-related macular degeneration and other eye diseases with one or more therapeutic agents |
| MX2021010599A (es) | 2019-03-05 | 2021-12-10 | Aerie Pharmaceuticals Inc | Composiciones farmaceuticas para el tratamiento de enfermedades o trastornos oculares. |
-
2020
- 2020-03-05 MX MX2021010599A patent/MX2021010599A/es unknown
- 2020-03-05 WO PCT/US2020/021136 patent/WO2020181060A1/en not_active Ceased
- 2020-03-05 CN CN202410368231.1A patent/CN118304422A/zh active Pending
- 2020-03-05 BR BR112021017436A patent/BR112021017436A2/pt unknown
- 2020-03-05 JP JP2021552571A patent/JP7570342B2/ja active Active
- 2020-03-05 KR KR1020217031760A patent/KR20210135560A/ko active Pending
- 2020-03-05 EP EP20766052.3A patent/EP3934646A4/en active Pending
- 2020-03-05 CN CN202410368463.7A patent/CN118286445A/zh active Pending
- 2020-03-05 CA CA3132635A patent/CA3132635A1/en active Pending
- 2020-03-05 US US16/810,149 patent/US12478577B2/en active Active
- 2020-03-05 CN CN202080033265.5A patent/CN113784727B/zh active Active
- 2020-03-05 AU AU2020232314A patent/AU2020232314C1/en active Active
-
2021
- 2021-09-02 MX MX2025002265A patent/MX2025002265A/es unknown
-
2024
- 2024-10-08 JP JP2024176401A patent/JP7838047B2/ja active Active
-
2025
- 2025-10-10 US US19/355,788 patent/US20260034056A1/en active Pending